ABCL earnings
Catalyst
ABCL earnings
ABCL earnings — 2026-05-11
Reported the quarter ending 2026-03-31: revenue $8M, diluted EPS $-0.14, net income $-43M (SEC filing, corroborated by the desk's provider cache). Across the print the stock moved -5.5% (close before → first close after).
Backfilled from filed financials — a record of the print, not an analyst read.
Related
8 events DateTypeEvent
Jun 4 Deep DiveABCL (AbCellera Biologics) Jun 25 ScanMonster Scan Jun 26 ScanMonster Scan Jun 30 ReactionObesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet Jul 7 ScanMonster Scan Jul 9 Desk NoteABCL — watch above $8.45 Jul 11 ScanMonster Scan Jul 13 Desk NoteVertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries No direct external sources are attached to this read.